[1] Shoulson I. Where do we stand on neuroprotection? Where do we go from here?[J]. Mov Disord, 1998,13:46~48.
[2] Caparros D, Cabaret M, Codefroy O, et al. PET study and neuropsychological assessment of a long-lasting post-encephalitic parkinsonism[J]. J Neural Transm, 1998, 105:489~495.
[3] Turjanski, Lees AJ, Brooks DJ, et al. Dopaminergic function in patients with posttraumatic parkinsonism:An 18F-dopa PET study[J]. Neurology, 1997, 49:183~189.
[4] Burn DJ, Brooks DJ. Nigral dysfunction in drug-induced parkinsonism:An 18F-dopa PET study[J].Neurology, 1993, 43:552~556.
[5] Antonini A,Leenders KL, Vontobel P, et al.Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease[J]. Brain,1997, 120:2187~2195.
[6] Kim Y, Kim JW, Ito K, et al. Idiopathic parkinsonism with superimposed manganese exposure:utility of positron emission tomography[J].Neurotoxicology, 1999, 20:249~252.
[7] Ito K, Morrish PK, Rakshi JS, et al. Statistical parametric mapping with 18F-dopa PET shows bilaterally reduced striatal and nigral dopaminergic function in early Parkinson's disease[J]. J Neurol Neurosurg Psychiatry, 1999, 66:754~758.
[8] Rakshi JS, Uema T, Ito K, et al. Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [18]dopa-PET study[J]. Brain, 1999, 122:1637~1650.
[9] Vingerhoets FJG, Snow BJ, Lee CS, et al.Longitudinal flurodopa positron emission tomography studies of the evolution of idiopathic parkinsonism[J].Ann Neurol, 1994, 36:759~764.
[10] Morrish PK, Sawle GV, Brooks DJ, et al. An 18F dopa-PET and clinical study of the rate of progressionin Parkinson's disease[J]. Brain, 1996, 119:585~591.
[11] Morrish PK, Rakshi JS, Bailey DL, et al. Measuringthe rate of progression and estimating the preclinicalperiod of Parkinson's disease with[18]-dopa PET[J]. J Neurol Neurosurg Psychiatry, 1998, 64:314~319.
[12] Hagell P, Schrag A, Piccini P, et al.Sequential bilateral transplantation in Parkinson's disease:effects of the second graft[J]. Brain, 1999, 122:112~132.
[13] Defer GL, Geny C,Ricolfi F, et al. Long-termoutcome of unilaterally transplanted parkinsonian patients:I. Clinical approach[J]. Brain, 1996, 119:41~50.